The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).

Employee Rating

2.3More
TypePublic
HQParis, FR
Founded1999
Size (employees)203 (est)
Websitecellectis.com
Cellectis was founded in 1999 and is headquartered in Paris, FR
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Cellectis

André Choulika

André Choulika

Chairman of the Board of Directors and CEO
Elsy Boglioli

Elsy Boglioli

COO
Philippe Duchateau

Philippe Duchateau

Chief Scientific Officer
Eric Dutang

Eric Dutang

CFO
Stephan Reynier

Stephan Reynier

Chief Regulatory and Compliance Officer
David Sourdive

David Sourdive

Executive Vice President Technical Operations
Show more

Cellectis Office Locations

Cellectis has offices in Paris and New York
Paris, FR (HQ)
8 Rue de la Croix Jarry
New York, US
430 E 29th St
Show all (2)
Report incorrect company information

Cellectis Financials and Metrics

Cellectis Revenue

Cellectis's revenue was reported to be $33.72 m in FY, 2017 which is a 40.3% decrease from the previous period.
USD

Revenue (FY, 2017)

33.7m

Revenue growth (FY, 2016 - FY, 2017), %

(40.3%)

Net income (FY, 2017)

(103.7m)

Cash (31-Dec-2017)

256.4m
USDFY, 2015FY, 2016FY, 2017

Revenue

56.4m56.4m33.7m

Revenue growth, %

0%(40%)

General and administrative expense

27.2m43.4m44.8m

R&D expense

52.4m78.5m79.2m
USDFY, 2015FY, 2016FY, 2017

Cash

314.2m254.6m256.4m

Accounts Receivable

6.0m3.6m2.8m

Inventories

118.0k118.0k250.0k

Current Assets

334.2m312.5m323.2m
USDFY, 2015FY, 2016FY, 2017

Net Income

(20.4m)(67.3m)(103.7m)

Depreciation and Amortization

1.7m2.2m3.4m

Inventories

(23.0k)50.0k(109.0k)

Accounts Payable

2.7m(4.4m)(335.0k)
USDY, 2017

Revenue/Employee

166.1k

Financial Leverage

1.2 x

P/E Ratio

(10.4)
Show all financial metrics

Cellectis Revenue Breakdown

Embed Graph

Cellectis revenue breakdown by geographic segment: 98.0% from France and 2.0% from Other

Report incorrect company information

Cellectis Online and Social Media Presence

Embed Graph
Report incorrect company information

Cellectis News and Updates

CAR-T Cell Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, and Forecasts 2018 To 2026

CAR-T Cell Therapy Market Expected To Exhibit Double Digit Growth During The Forecast Period Posted via Industry Today. Follow us on Twitter @IndustryToday

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Market (Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Cellectis) Consumption, Recent Developments, and Comprehensive Forecast

ReportsWeb.com added “Global CRISPR Market Size Status and Forecast 2022” to its vast collection of research Database. The report classifies the global CRISPR Market in a precise manner to offer detailed insights into the aspects responsible for augmenting as well as restraining market growth. Poste…
Report incorrect company information

Cellectis Blogs

Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing

December 10, 2018 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the appointment of William (Bill) Monteith to the role of Senior Vice President U.S. Ma…

Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018

UCART123 in Phase 1 clinical trial for AML and BPDCN patients; UCART22 Phase 1 study protocol approved by FDA for B-ALL patients; UCART19 ASH abstract by partner Servier shows continued progress of first clinical allogeneic CAR T-cell program for ALL patients; UCARTCS1 clinical trial expected to …

CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board

September 19, 2018 – New York – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that Stephan A. Grupp, MD, Ph.D., a leading pediatric oncologist at Children's Hospital of Phi…

Calyxt Appoints CEO, Jim Blome,  Former President & CEO of Bayer CropScience LP

Minneapolis-St. Paul, Minn. and New York, NY, September 18, 2018 – Calyxt, Inc. (NASDAQ: CLXT) and Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) announced today the appointment of James A. Blome, former President and CEO of Bayer CropScience LP (North America), as Chief Executive Officer of…

Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO

Calyxt to host conference call on Wednesday, August 22, 2018 at 8:30 a.m. ET – 7:30 a.m. CT Minneapolis-St. Paul, Minn. and New York, NY, August 22, 2018 – Calyxt, Inc. (NASDAQ: CLXT) and Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) announced today its Board of Directors has appointed Yve…

Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer

August 2nd, 2018 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the rol…
Show more

Cellectis Company Life and Culture

Report incorrect company information

Cellectis Frequently Asked Questions

  • When was Cellectis founded?

    Cellectis was founded in 1999.

  • Who are Cellectis key executives?

    Cellectis's key executives are André Choulika, Elsy Boglioli and Philippe Duchateau.

  • How many employees does Cellectis have?

    Cellectis has 203 employees.

  • What is Cellectis revenue?

    Latest Cellectis annual revenue is $33.7 m.

  • What is Cellectis revenue per employee?

    Latest Cellectis revenue per employee is $166.1 k.

  • Who are Cellectis competitors?

    Competitors of Cellectis include Allogene Therapeutics, MyoKardia and Athersys.

  • Where is Cellectis headquarters?

    Cellectis headquarters is located at 8 Rue de la Croix Jarry, Paris.

  • Where are Cellectis offices?

    Cellectis has offices in Paris and New York.

  • How many offices does Cellectis have?

    Cellectis has 2 offices.